Cathie Wood’s ARK Invest Shifts Focus to Biotech, Trims Other Holdings
ARK Invest, led by Cathie Wood, made significant moves in the biotech sector on September 17, 2025. The firm's flagship ARK Innovation ETF (ARKK) allocated $20.8 million to CRISPR Therapeutics (CRSP) and $11.2 million to BEAM Therapeutics (BEAM), reinforcing its conviction in genomic medicine.
The ARK Genomic Revolution ETF (ARKG) added positions in Atai Life Sciences ($1.85 million) and Arcturus Therapeutics ($411,000), while expanding its stake in Intellia Therapeutics ($2.6 million). These purchases highlight Wood's continued bet on disruptive healthcare technologies.
Beyond biotech, ARK's autonomous technology and space exploration funds jointly invested $2.8 million in AeroVironment, demonstrating the firm's diversified approach to innovation investing.
